Conference Call HighlightsAnesthesia - all facilities are open and operational. Early Q3 was impacted due to closures. By August they were operating at full volumes and continue to be. Outpatient care and ASCs have been able to process high volumes of patients still while adhering to safety protocols. Optimistic that they could deal with COVID disruptions and they don't expect a March/April type shut down again.
O'Regan Product Sales - they view this product as best in class and are still touting that given the market size this segment could represent over $100MM in Sales Revenues for CRH. New initiatives underway for marketing to GI medical community.
Payor Strategy - non contracted case mix trending towards single digit % of Sales
Revenue per Case - no guidance being provided given COVID disruptions but they are happy with the trend
Capital Spend - $19MM spent to date on acquisitions, may not reach 2019 levels given COVID disruptions
CMS Changes - number of proposed changes to procedure fees and primary care fees in 2021 across all medical professions, too early to tell
Acquisiton Pipeline - the pipeline remains active and robust, good dialog and in late stages of several deals